Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

2023127 citationsJournal Articlehybrid Open Access

Authors

Emmanuel S. Antonarakis · University of Minnesota

Se Hoon Park · Samsung Medical Center

Jeffrey C. Goh · Royal Brisbane and Women's Hospital

Sang Joon Shin · Severance Hospital

Jae‐Lyun Lee · Ulsan College

Niven Mehra · Radboud University Nijmegen

Ray McDermott ·

Abstract

Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.

Topics & Keywords

Prostate Cancer Treatment and Research Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 22, pp. 3839-3850

DOI: 10.1200/jco.23.00233

Field-Weighted Citation Impact: 32.79